IPM Take
NAD has become one of the most commercially successful molecules in the healthy-ageing conversation because the story is seductively simple: NAD declines as people age, restoring it should therefore help restore youthful cellular function.
Human biology is refusing to cooperate with the simplicity.
A study published in Nature Metabolism measured whole-blood NAD in more than 1,000 adults and found no progressive age-related decline among healthy participants. Levels were broadly stable in men and actually increased modestly with age in women. The clearer difference appeared not between young and old, but between healthy people and those with cardiovascular disease, particularly hypertension.
That does not make whole-blood NAD a cardiovascular biomarker, and it certainly does not establish NAD supplementation as a cardiovascular treatment. The study was observational, disease groups were relatively small and the authors explicitly warn against drawing causal conclusions.
But the findings strike at an important distinction increasingly blurred by the wellness market: raising a biomarker is not the same thing as correcting a deficiency, and correcting a biomarker is not the same thing as improving health.
Nicotinamide mononucleotide and nicotinamide riboside can raise circulating NAD-related measures. This study confirms that supplementation can push whole-blood NAD well above the range seen naturally in most unsupplemented participants.
What remains uncertain is whether healthy people need that increase, what happens when high concentrations are sustained for years and whether the relevant biology in blood reflects what is happening inside muscle, brain, heart or other tissues.
The new evidence therefore does not close the NAD story.
It makes the story more specific.
If NAD-targeted therapy has a future, it may be in selected diseases with demonstrable NAD dysregulation rather than as a universal antidote to growing older.
Executive Summary
A Nature Metabolism study published on 4 November 2026 examined whether whole-blood nicotinamide adenine dinucleotide, or NAD, declines with healthy ageing and whether concentrations differ in chronic disease.
Researchers conducted 1,340 NAD measurements across 1,068 adults, including 636 women and 432 men.
In the main cross-sectional analysis, blood samples were collected under standardised morning fasting conditions. Participants without chronic disease and without reported NAD-boosting supplement use were analysed separately from participants with medication-verified chronic disease.
Among healthy men, whole-blood NAD showed no significant progressive association with age.
Among healthy women, NAD unexpectedly showed a modest increase with age, with sensitivity analyses preserving the overall statistical conclusion.
The disease analysis produced a different pattern. Whole-blood NAD was lower in participants with cardiovascular disease and hypertension than in healthy comparison groups. In men with cardiovascular disease, NAD also declined with age, while in women the increase observed during healthy ageing disappeared.
The researchers therefore concluded that whole-blood NAD appeared to track cardiovascular health more closely than chronological ageing.
That finding is consistent with a separate 2026 Nature Metabolism study examining seven human cohorts, which also found that whole-blood NAD+ remained broadly stable with age.
The new study additionally examined supplementation. Twenty-two healthy participants reported using NAD-boosting supplements under uncontrolled real-world conditions. Six, or 27%, had NAD concentrations of 38 to 58 µM, approximately two to three times the usual unsupplemented range.
In an exploratory longitudinal experiment involving only two individuals, self-administered NMN at 1,000 mg per day increased whole-blood NAD from approximately 19 to 20 µM at baseline to approximately 51 to 56 µM within two weeks.
These supplementation experiments demonstrate biochemical response, not clinical benefit.
The study was not designed to determine whether low NAD causes hypertension or cardiovascular disease, whether supplementation reverses either condition, or whether chronically maintaining unusually high NAD levels is beneficial or safe.
The authors explicitly state that their findings provide no broad rationale for NAD-boosting interventions in healthy adults based on chronological age alone.
Why it matters
- HTA bodies: NAD-targeted products illustrate why biomarker modification and clinical efficacy must remain separate evidentiary questions. Future assessment should distinguish whether an intervention raises circulating NAD, corrects a disease-specific biological deficit and ultimately changes clinically meaningful outcomes. A higher laboratory value alone cannot establish therapeutic benefit.
- Payers: Current evidence does not justify reimbursement of NAD-boosting supplementation as routine cardiovascular prevention or healthy-ageing treatment. Disease-specific trials may eventually create a different case, particularly if defined populations with hypertension or other conditions show measurable NAD dysregulation and clinically meaningful responses to intervention.
- Industry / innovation partners: The commercial opportunity may need to move away from universal “anti-ageing” positioning and toward precision development. Identifying which tissues, diseases and patients actually have relevant NAD deficits could produce more defensible therapeutic programmes than treating chronological age itself as the indication.
Few molecules have travelled from cellular biochemistry to consumer wellness as successfully as NAD.
Nicotinamide adenine dinucleotide is essential to basic cellular metabolism. It participates in redox reactions that allow cells to generate and use energy and serves as a substrate for enzymes involved in DNA repair, signalling and other biological processes.
That biology is real.
The commercial narrative built around it is much broader.
Animal studies and human tissue research have suggested that NAD can decline with age in some organs, contributing to an increasingly popular hypothesis that restoring NAD might counter parts of biological ageing. Supplements containing NAD precursors such as nicotinamide riboside and nicotinamide mononucleotide have consequently moved into a growing market built around longevity, metabolic health and cellular rejuvenation.
The logic often begins from a simple premise: ageing depletes NAD.
A new Nature Metabolism study suggests that, in whole blood at least, that premise may be wrong.
Researchers in Lithuania measured whole-blood NAD across 1,068 adults, separating people without known chronic disease from participants whose reported conditions were supported by compatible medication use.
The healthy population produced the first surprise.
Among men, NAD did not progressively fall with age.
Among women, the relationship moved in the opposite direction. Whole-blood NAD increased modestly as age increased.
That finding should not be overgeneralised to every tissue in the body.
NAD metabolism is compartmentalised. A concentration measured in circulating blood cells does not necessarily tell researchers what is happening in skeletal muscle, brain, skin, liver or myocardium.
Previous studies have reported age-associated NAD changes in several tissues, and the authors of the new paper explicitly state that their blood findings do not contradict those tissue-specific observations.
What they do challenge is the assumption that the human body experiences one uniform systemic NAD decline that can be captured with a blood test and corrected universally through supplementation.
That distinction matters because whole blood is the easiest compartment to measure.
If blood NAD is used commercially as evidence that somebody is “NAD deficient”, the validity of that interpretation depends on knowing what normal blood NAD should do with age.
The new study suggests that simply being older does not necessarily mean having less.
It also reinforces another study published in the same journal earlier in 2026.
That independent investigation quantified NAD+ across seven human cohorts using a validated mass-spectrometry approach and similarly found that whole-blood NAD+ remained remarkably stable with age. Lifestyle interventions did not produce consistent age-related changes either, although nicotinamide riboside supplementation did raise NAD+ as expected.
Together, the studies make it increasingly difficult to treat falling whole-blood NAD as an established universal biomarker of healthy human ageing.
But the Lithuanian study also found something potentially more interesting.
The difference appeared when disease entered the picture.
Among participants with cardiovascular disease, whole-blood NAD concentrations were lower than among healthy participants. Hypertension produced the clearest disease-specific signal in both sexes.
The trajectory changed as well.
Healthy men showed relatively stable NAD with age, whereas men with chronic disease showed a decline. Healthy women showed increasing NAD with age, while women with chronic disease lost that pattern.
When the disease population was divided into diagnostic groups, reductions remained most evident in cardiovascular disease and hypertension.
That shifts the biological question.
Instead of asking whether NAD is a marker of getting older, researchers may need to ask whether it is a marker of particular pathological states that become more common with age.
The difference is fundamental.
Age and age-related disease are correlated, but they are not interchangeable.
If hypertension becomes increasingly common among older adults and hypertension itself is associated with lower NAD, a study that does not separate healthy ageing from disease could mistakenly conclude that NAD falls because of age.
The new authors explicitly offer this as one possible explanation for conflicting results in earlier research.
It would be a familiar epidemiological error.
Older populations contain more disease. If disease is not adequately separated from age, biomarkers associated with disease can begin to look like biomarkers of ageing itself.
That does not yet make low NAD a cardiovascular biomarker.
The study was cross-sectional, so it cannot establish which came first.
Hypertension might contribute to altered NAD metabolism. Low NAD might participate in pathways that promote vascular dysfunction and hypertension. Medication could influence the measured concentration. Another biological factor might affect both.
The investigators tried to strengthen disease classification by requiring self-reported diagnoses to be supported by compatible medication use, but medication itself then becomes a potential confounder.
The authors acknowledge exactly that limitation.
The disease groups were also considerably smaller than the healthy cohort. Of the 1,068 participants, 243 met the chronic-disease criteria, and only 197 were included in the detailed disease stratification. Several individual diseases contained too few participants to analyse robustly.
Type 2 diabetes, for example, could not be meaningfully tested because the sex-specific sample sizes were too small.
The study therefore should not be read as evidence that NAD is uniquely linked to cardiovascular disease and unrelated to other chronic conditions.
Cardiovascular disease was simply the best-powered disease category in this dataset.
The supplementation findings create a second policy issue.
Among healthy participants, only 22 reported taking NAD boosters, but supplementation was associated with substantially higher whole-blood NAD concentrations. Six supplement users reached values between 38 and 58 µM, around two to three times the typical range observed among unsupplemented participants.
The investigators then conducted an exploratory longitudinal experiment involving two people who were already independently taking 1,000 mg of NMN per day.
Their whole-blood NAD increased rapidly, from approximately 19 to 20 µM before supplementation to around 51 to 56 µM.
The biochemical message is straightforward.
NAD precursors can raise the thing they are designed to raise.
The clinical message is much less obvious.
Medicine has repeatedly learned that improving a surrogate biomarker does not guarantee better clinical outcomes. Raising HDL cholesterol pharmacologically did not automatically prevent cardiovascular events. Suppressing ventricular arrhythmias after myocardial infarction once appeared mechanistically logical and ultimately increased mortality with some drugs.
Biology rewards evidence, not plausibility.
The important question for NAD supplementation is therefore not whether supplementation raises NAD.
It does.
The question is what sustained elevation accomplishes in humans.
The new study offers no answer.
Its two-person NMN component was designed to characterise the speed and magnitude of the blood response, not health outcomes. It had no placebo group and no capacity to measure efficacy or long-term safety.
Even the significance of producing unusually high NAD concentrations remains unknown.
The authors are unusually explicit about that uncertainty.
Most NAD-precursor trials have been relatively small and short. Long-term consequences of maintaining concentrations well above the naturally observed range remain poorly characterised.
The paper does not claim those high levels are harmful.
It does, however, identify biological reasons not to assume that “more NAD” is automatically better indefinitely. NAD metabolism intersects with inflammatory signalling, immune biology and pathways relevant to cancer, making long-term safety an empirical question rather than something that can be inferred from the molecule’s essential physiological role.
That point matters in a consumer market where the distinction between restoring normal physiology and pushing a biological pathway beyond its ordinary range can disappear.
A molecule can be essential and still not become more beneficial in direct proportion to its concentration.
Water is essential.
So is glucose.
Physiology is governed by regulation, not maximalisation.
The broader clinical literature around NAD precursors already reflects that tension.
A 2025 Nature Metabolism review concluded that preclinical evidence for NAD restoration is extensive, but human trials have so far shown limited and inconsistent efficacy across ageing-related outcomes. The authors highlighted the need for much better understanding of tissue-specific NAD metabolism and warned against straightforward extrapolation from rodents to humans.
Some early trials nevertheless provide reasons to continue investigating disease-specific applications.
A small randomised crossover trial published in 2018 showed that six weeks of nicotinamide riboside supplementation was well tolerated in healthy middle-aged and older adults and increased NAD-related metabolites. Exploratory analyses suggested possible reductions in systolic blood pressure and arterial stiffness, particularly among participants with higher baseline blood pressure.
The trial included only 24 participants for those cardiovascular assessments and was not powered to establish cardiovascular efficacy.
Its proper legacy is a hypothesis.
The new disease-association data make that hypothesis more interesting.
If hypertension is genuinely associated with altered NAD metabolism, NAD-targeted therapy could conceivably have greater biological relevance in defined hypertensive populations than in healthy people taking supplements solely because they are older.
That is precisely the kind of distinction precision medicine is supposed to make.
Instead of assuming everyone above a certain age shares the same molecular deficit, researchers identify a biological abnormality in a defined population, establish whether it contributes causally to disease and then test whether correcting it improves outcomes.
The sequence matters.
The supplement market has often reversed it.
Products became available first. Blood NAD testing followed. The assumption that age creates deficiency helped provide a biological explanation for why otherwise healthy consumers might want supplementation.
Now human data are beginning to interrogate that premise more critically.
There is another methodological complication.
The new study measured total whole-blood NAD, the combined pool of NAD+ and NADH, using dried blood spots. Drying changes the NAD+/NADH ratio, although the investigators performed extensive validation suggesting that the total NAD pool remained stable and correlated strongly with measurements from liquid whole blood and mass spectrometry.
That makes the technique useful for total NAD measurement.
It does not make whole blood a window into every tissue.
The authors repeatedly stress that distinction, and it may become increasingly important as consumer NAD testing expands.
A blood test can tell somebody what is in the blood sample.
Whether that number measures “biological age”, tissue NAD depletion or a need for supplementation requires separate evidence.
The latest data provide little support for the first interpretation.
They are more intriguing for the second question of disease.
That changes where the research agenda should go next.
Larger cohorts need to establish whether reduced blood NAD consistently appears in hypertension and cardiovascular disease across populations. Longitudinal studies need to determine whether lower NAD precedes disease development or emerges after disease begins. Mechanistic studies need to clarify whether blood NAD reflects relevant changes in vascular or cardiac tissue.
And intervention trials need to enrol the populations most likely to benefit.
If NAD precursors lower blood pressure, improve arterial function or influence cardiovascular events in defined patients, the therapeutic story becomes important regardless of whether NAD declines in healthy ageing.
If raising NAD produces no meaningful clinical benefit, the biomarker association will remain biologically interesting but therapeutically limited.
The study also deserves transparency around its research setting.
The authors reported no specific funding for the work, but several were current or former employees of SensoLife, which produces NAD testing technology, or LifeLab1, the laboratory involved in testing. Bloodo provided dried-blood-spot collection kits at no cost.
Those relationships do not invalidate the results, and the assay underwent extensive cross-platform and multi-site validation.
They do make independent replication especially valuable, particularly if blood NAD testing develops into a larger commercial market.
Fortunately, independent evidence is already moving in the same direction on the ageing question.
The May 2026 Nature Metabolism study from separate research groups also concluded that whole-blood NAD+ does not decline consistently with age.
That convergence is more important than either study alone.
It suggests that one of the cleanest marketing narratives around NAD may need rewriting.
Ageing biology remains extraordinarily complex. NAD metabolism almost certainly matters within it, and specific tissues may undergo changes not visible in blood.
But the increasingly available human evidence does not support treating low whole-blood NAD as an inevitable consequence of healthy ageing.
Nor does it support treating supplementation as a universal correction for older adults.
The more defensible future may be narrower and scientifically stronger: determine where NAD metabolism is genuinely disrupted, establish whether that disruption matters to disease and test interventions in those populations.
That approach is less marketable than promising to replenish youth.
It is also much closer to medicine.
The new evidence does not make NAD irrelevant to ageing or cardiovascular disease. It makes a more demanding point: before medicine tries to restore NAD, it needs to establish who is actually deficient, where the deficit exists and whether correcting it improves anything that matters.

